Triflusal vs. aspirin
This article was originally published in The Tan Sheet
Executive Summary
Aspirin and anti-clotting drug triflusal are similarly effective in secondary stroke prevention but triflusal poses less hemorrhage risk, according to two studies presented. Triflusal, an antiplatelet agent structurally related to aspirin, was developed in Spain about 20 years ago and is licensed for use in parts of Europe, Asia and Latin America; approval never has been sought in the U.S., according to the American Stroke Association. One study of 429 patients was conducted in Buenos Aires, Argentina; another trial looked at 2,108 patients in Spain and Portugal. Both compared the efficacy of triflusal 600 mg to aspirin 325 mg among subjects who had suffered a recent TIA or stroke